InfuSystem Investor Presentation Highlights 22.9% TTM Adjusted EBITDA Margin
InfuSystem reported a 22.9% TTM adjusted EBITDA margin, with $144.4M in TTM revenue and $33.1M in 2026 adjusted EBITDA. The company aims for a 22%-25% long-term margin range, citing ERP investments and billing efficiencies. Wound Care revenue grew 103% YoY in 2025. InfuSystem has $64.1M in liquidity and serves over 100,000 patients annually.
How this was made
The 30-second read
Why it matters
The new margin guidance and liquidity metrics suggest improved operational efficiency and financial stability.
Market read
Fresh earnings‑type guidance for a mid‑cap healthcare stock, likely to influence trading decisions today.
What to watch
Potential execution risk on ERP investments and payer contract renewals.
Background
InfuSystem Holdings, Inc. is a specialty medical device company focused on wound‑care treatments.
Ticker impact
InfuSystem presented its latest adjusted EBITDA margin of 22.9% and set a 22%-25% long‑term target, plus disclosed TTM revenue of $144.4M and liquidity figures.
likely upward pressure as investors price in higher margins and strong cash flow
The disclosed margin expansion and solid liquidity are fresh, material data for a mid‑cap healthcare company, prompting potential buying interest.
Market effects
May lift sentiment for the broader wound‑care and specialty medical device sector.
U.S. healthcare equities could see modest gains.
Limited to U.S. markets; no direct global impact.
Counterpoint
If margin guidance is already priced in, the stock could face a short‑term pullback.
Key entities
- companyInfuSystem Holdings, Inc.
Specialty medical device firm reporting guidance.
